GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (FRA:45O) » Definitions » Net Income Including Noncontrolling Interests

Orgenesis (FRA:45O) Net Income Including Noncontrolling Interests : €-47.56 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Orgenesis's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was €-9.21 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was €-47.56 Mil.

Orgenesis Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Orgenesis's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Net Income Including Noncontrolling Interests Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.44 0.48 -15.98 -11.49 -59.53

Orgenesis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.83 -28.79 -3.49 -6.07 -9.21

Orgenesis Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-47.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Orgenesis's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis (FRA:45O) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (FRA:45O) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
CRIS VIRX ENLV RGLS CRBP PTN CLRB AGE CADL MRKR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ORGS:USA
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Website
https://www.orgenesis.com
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis (FRA:45O) Headlines

No Headlines